Luigi Bonfatti | Executive Advisor
RVMC (Regionalized Vaccine Manufacturing Collaborative)

Luigi Bonfatti, Executive Advisor, RVMC (Regionalized Vaccine Manufacturing Collaborative)

Luigi Bonfatti is Executive Advisor at RVMC (Regionalized Vaccine Manufacturing Collaborative). As member of RVMC Leadership he has global accountability on industry (and industry associations) engagement as well as for Asia regionalization agenda. Before joining RVMC, Luigi has been supporting Chiesi Farmaceutici, Italian largest pharma company, in managing the integration of its largest acquisition to date (a fully fledged rare disease company) and adjust its operating and governance business models. Prior to that, Luigi has spent 25 years at GSK Vaccines in a variety of senior roles in business development, supply, marketing and strategy of growing importance. During the last 8 years at GSK he created and grew a self-standing business unit in charge of integrations, divestments and strategic partnerships. As general manager of this business unit, Luigi was overseeing commercial and industrial partnerships and product transfers allowing him to have a unique end-to-end understanding of the vaccine industry and value chain. Luigi holds a chemical engineering degree from Polytechnic School of Brussels University as well as an MBA from Solvay Business School.

Appearances:



Main Congress Day 3 - 24th April @ 09:25

Regionalized Vaccine manufacturing and stockpiling to support routine immunization and outbreak response

Main Congress Day 3 - 24th April @ 11:30

The Best Defense Against Infectious Disease: Ensuring Vaccine Access and Confidence

  • What would a new model look like for innovative vaccine development so that we do not rely on reactive funding and resources?
  • Importance of communications and trust – esp. when you have different vaccine options
  • Could we be leveraging “warm places” to support NTDs and tackle local diseases with these distributed plants?
  • How to keep this sustainable even when governments change and during war?
  • How are available resources being used to address gaps in the pipeline or supply chain that are a barrier to access?
last published: 22/Apr/25 15:25 GMT

back to speakers